logo-loader

Wellbeing Digital Science says KGK subsidiary enters into research contract with Halucenex to test efficacy of psilocybin on PTSD

Published: 06:35 21 Jul 2022 EDT

Wellbeing Digital Sciences -
Wellbeing CEO Najla Guthrie said the research agreement will move the industry closer to creating alternative medicines for a growing population base

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly-owned subsidiary KGK Sciences Inc has entered into a research services agreement with Halucenex Life Sciences Inc, a psychedelic subsidiary of Creso Pharma.

"We are thrilled to be working with Halucenex for their planned phase II clinical trials to test the efficacy of psilocybin on treatment-resistant Post Traumatic Stress Disorder (PTSD)," Najla Guthrie, CEO of Wellbeing and KGK, said in a statement.

Under the agreement, KGK will perform research services, including the development of the clinical trial protocol, preparations towards the phase II clinical trials, data management and validation, statistical analysis and drafting of the final report.

READ: Wellbeing Digital Sciences appoints Natalie Dolphin as VP of marketing and investment relations

“Over the past 25 years, we have successfully helped hundreds of companies with custom-designed clinical trials and claim substantiation strategies that move products efficiently into the global markets,” Guthrie noted.

This research agreement will move the industry closer to creating alternative medicines for a growing population base, she added.

"KGK is a leading contract research organization offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabinoid, hemp and psychedelic industries," said Bill Flemming, founder and CEO of Halucenex.

"We are confident that KGK's role will enable us to make considerable progress towards creating alternative treatment solutions to current pharmacological interventions," he added.

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.

Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.

Contact the author at jon.hopkins@proactiveinvestors.com

Wellbeing Digital Sciences announces company has received Cannabis License...

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) CEO Najla Guthrie joined Steve Darling from Proactive to share news Health Canada has awarded the company’s subsidiary KGK Science a Cannabis Research License. Guthrie telling Proactive this license is for its new state-of-the-art facility...

on 12/15/2022